Valuation : Protalix BioTherapeutics, Inc.

Market Cap 205M 177M 166M 151M 284M 19.52B 286M 1.96B 767M 9.87B 768M 752M 32.77B P/E 2026 *
13.4x
P/E 2027 * 46.2x
Enterprise Value 205M 177M 166M 151M 284M 19.52B 286M 1.96B 767M 9.87B 768M 752M 32.77B EV / Sales 2026 *
2.56x
EV / Sales 2027 * 3x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-2.68%
1 week+6.72%
Current month+7.17%
1 month+11.89%
3 months+20.38%
6 months-11.81%
Current year+41.11%
1 week 2.34
Extreme 2.34
2.65
1 month 2.17
Extreme 2.17
2.7
Current year 1.72
Extreme 1.72
3.19
1 year 1.52
Extreme 1.5201
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap.
19/12/25 Buy

Chief Executive Officer

56,000 0.0696%
18/11/25 Sell

Director

168 0.0002%
03/09/25 Free

Chief Operating Officer

75,000 0.0941%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%+6.72%+63.87%+30.26% 205M
-0.13%-6.44%+60.34%+112.06% 1,047B
+0.85%-0.81%+51.29%+63.13% 646B
-1.03%-3.58%+21.43%+73.10% 451B
-1.46%-4.50%+37.80%+37.41% 355B
-0.72%-2.89%+22.32%+36.62% 291B
-1.19%-2.21%+1.53%+10.79% 252B
-1.05%-1.57%+50.30%+66.55% 234B
+0.08%-1.78%-17.64%-54.36% 203B
-2.14%-0.30%+28.95%+86.27% 181B
Average -0.95%-1.44%+32.02%+46.18% 365.95B
Weighted average by Cap. -0.46%-3.46%+38.17%+65.00%

Financials

2026 *2027 *
Net sales 79.8M 68.88M 64.56M 58.95M 111M 7.61B 111M 765M 299M 3.85B 300M 293M 12.78B 68.19M 58.87M 55.18M 50.38M 94.78M 6.5B 95.22M 654M 255M 3.29B 256M 250M 10.92B
Net income 15.38M 13.27M 12.44M 11.36M 21.37M 1.47B 21.47M 147M 57.6M 742M 57.72M 56.47M 2.46B 4.46M 3.85M 3.61M 3.3M 6.2M 426M 6.23M 42.81M 16.72M 215M 16.75M 16.39M 715M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
28/08/26 $2.540 -2.68% 490,228
27/08/26 $2.610 +5.24% 1,293,530
26/08/26 $2.480 +3.33% 1,023,782
25/08/26 $2.400 -0.41% 497,742
24/08/26 $2.410 +1.26% 409,933
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.540USD
Average target price
11.00USD
Spread / Average Target
+333.07%

Quarterly revenue - Rate of surprise